Lauren Mastrocola - Praxis Precision VP Officer

PRAX Stock  USD 69.90  3.34  5.02%   

Insider

Lauren Mastrocola is VP Officer of Praxis Precision Medicines
Address 99 High Street, Boston, MA, United States, 02110
Phone617 300 8460
Webhttps://praxismedicines.com

Latest Insider Transactions

2024-11-14Disposed of 5188 shares @ 81.78View

Praxis Precision Management Efficiency

The company has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6434) %, meaning that it created substantial loss on money invested by shareholders. Praxis Precision's management efficiency ratios could be used to measure how well Praxis Precision manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.47 in 2024. Return On Capital Employed is likely to drop to -1.84 in 2024. At this time, Praxis Precision's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 108.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3 M in 2024.
Praxis Precision Medicines currently holds 2.5 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Praxis Precision Med has a current ratio of 4.47, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Praxis Precision's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jack AndersRevolution Medicines
48
Walter ReiherRevolution Medicines
N/A
Jennifer MichaelsonCullinan Oncology LLC
57
Deepika PharmDPmv Pharmaceuticals
48
Behrad DerakhshanEdgewise Therapeutics
44
CPA CPAStoke Therapeutics
63
Joan WoodStoke Therapeutics
N/A
Isabel AznarezStoke Therapeutics
52
Anne LesagePharvaris BV
63
Sanjay ChandaAN2 Therapeutics
59
Paul MDAN2 Therapeutics
54
Michael AlleyAN2 Therapeutics
N/A
Jeffrey TrigilioCullinan Oncology LLC
40
Josh EizenAN2 Therapeutics
N/A
Gene KimDyne Therapeutics
47
Thomas ShenkPmv Pharmaceuticals
77
Alexander ZurcherMolecular Partners AG
49
Hing WongHCW Biologics
70
MBA MDCullinan Oncology LLC
51
Jacquelyn JDCullinan Oncology LLC
46
MBA MDEliem Therapeutics
63
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company was incorporated in 2015 and is based in Boston, Massachusetts. Praxis Precision operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. Praxis Precision Medicines (PRAX) is traded on NASDAQ Exchange in USA. It is located in 99 High Street, Boston, MA, United States, 02110 and employs 82 people. Praxis Precision is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Praxis Precision Med Leadership Team

Elected by the shareholders, the Praxis Precision's board of directors comprises two types of representatives: Praxis Precision inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Praxis. The board's role is to monitor Praxis Precision's management team and ensure that shareholders' interests are well served. Praxis Precision's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Praxis Precision's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dr B, CoFounder Officer
Timothy Kelly, CFO Treasurer
Nicole Sweeny, Chief Officer
Kelly McCue, Chief Officer
Alyssa Wyant, Chief Officer
Megan Sniecinski, Chief Officer
Lauren Mastrocola, VP Officer
Brian Spar, Chief Staff
Alex JD, General Secretary
Marcio MBA, CEO President
Karl Hansen, Chief Officer
Alex Kane, VP Communications

Praxis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Praxis Precision a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Praxis Stock Analysis

When running Praxis Precision's price analysis, check to measure Praxis Precision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Praxis Precision is operating at the current time. Most of Praxis Precision's value examination focuses on studying past and present price action to predict the probability of Praxis Precision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Praxis Precision's price. Additionally, you may evaluate how the addition of Praxis Precision to your portfolios can decrease your overall portfolio volatility.